ACRV

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.60 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Acrivon Therapeutics Inc revenue for the last quarter amounts to -19.69M USD, decreased -21.69 % YoY.

Acrivon Therapeutics Inc. EPS for the last quarter amounts to -13182000.00 USD, decreased -28.01 % YoY.

Acrivon Therapeutics Inc (ACRV) has 75 emplpoyees as of January 09 2026.

Today ACRV has the market capitalization of 60.90M USD.